[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06096779":3,"trial-entities:NCT06096779":524,"trial-summary:NCT06096779":527},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":41,"primary_purpose":42,"phases":43,"enrollment_info":45,"interventions":48,"primary_outcomes":62,"secondary_outcomes":67,"sex":68,"minimum_age":69,"maximum_age":70,"healthy_volunteers":15,"eligibility_criteria":71,"std_ages":116,"locations":119,"central_contacts":516,"overall_officials":517,"references":522,"see_also_links":523},"NCT06096779","ML44719","A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis","A Phase II, Open-label, Multi-cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis","ACTIVE_NOT_RECRUITING","2027-12-30","2026-07","2026-07-10","2024-07-15","Genentech, Inc.","INDUSTRY",false,"The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.","This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic HCC who have Child-pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.",[19],"Hepatocellular Carcinoma",[21,22,23,24,19,25,26,27,28,29,5,30,31,32,33,34,35,36,37,38,39,40],"Cirrhosis","Liver Cancer","Liver Tumor","Child-pugh B","Atezolizumab","Bevacizumab","Immune Checkpoint Inhibitor","Digestive System Neoplasms","Kirros","Liver Disease","Genentech","Immunotherapy","CPB","CPB 7","CPB 8","Tecentriq","Avastin","HCC","Cirrhotic Liver","Fatty Liver","INTERVENTIONAL","TREATMENT",[44],"PHASE2",{"count":46,"type":47},30,"ACTUAL",[49,57],{"type":50,"name":25,"description":51,"armGroupLabels":52,"otherNames":55},"DRUG","Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.",[53,54],"Cohort A: Atezolizumab+Bevacizumab","Cohort B: Atezolizumab",[56],"Tecentriq; RO5541267",{"type":50,"name":26,"description":58,"armGroupLabels":59,"otherNames":60},"Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg\u002Fkg) by IV infusion on Day 1 of each 21-day cycle.",[53],[61],"Avastin; RO4876646",[63],{"measure":64,"description":65,"timeFrame":66},"Percentage of Participants With Adverse Events (AEs)","An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) in Cohorts A and B.","Baseline through the end of the study (up to approximately 36 months)",[],"ALL","18 Years",null,{"inclusion":72,"exclusion":89,"raw_text":115},[73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88],"Locally advanced or metastatic and\u002For unresectable HCC with diagnosis confirmed by histology\u002Fcytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants","Disease that is not amenable to curative surgical and\u002For locoregional therapies","No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and\u002For unresectable HCC","Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)","Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days prior to initiation of study treatment","Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment","Adequate hematologic and end-organ function","Life expectancy of at least 12 weeks","Female participants of childbearing potential must be willing to avoid pregnancy and egg donation","Absolute neutrophil count ≥1.0 x 10\\^9 per liter (\u002FL) (≥1000 per microliter \\[\u002FμL\\]) without granulocyte colony-stimulating factor support","Platelet count ≥ 50 × 109\u002FL (50,000\u002FμL) without transfusion","Hemoglobin ≥ 80 grams per liter (g\u002FL) (8 grams per deciliter \\[g\u002FdL\\]) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal (ULN)","Serum bilirubin ≤ 3 × ULN","Creatinine clearance ≥ 50 milliliters per minute (mL\u002Fmin) (calculated using the Cockcroft-gault formula)","Serum albumin ≥ 20 g\u002FL (2.0 g\u002FdL) without transfusion in the prior 3 months","International normalized ratio (INR) ≤2.3",[90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114],"Pregnancy or breastfeeding","Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies","Treatment with investigational therapy within 28 days prior to initiation of study treatment","Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure","Treatment with systemic immunostimulatory agents","Treatment with systemic immunosuppressive medication","Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment","Inadequately controlled hypertension","Active or history of autoimmune disease or immune deficiency","History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan","Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation","Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded","Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC","Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases","Prior allogeneic stem cell or solid organ transplantation","Actively listed for liver transplantation","Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)","Untreated or incompletely treated esophageal and\u002For gastric varices with bleeding or that are at high risk for bleeding","A prior bleeding event due to esophageal and\u002For gastric varices within 6 months prior to initiation of study treatment","Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment","Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment","History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B","Diagnostic paracentesis is allowed. Therapeutic paracentesis: one large volume paracentesis prior to enrollment with diuretic controlled ascites is allowed.","Participants with ascites controlled on diuretics are allowed","History of spontaneous bacterial peritonitis within last 12 months","General Inclusion Criteria:\n\n* Locally advanced or metastatic and\u002For unresectable HCC with diagnosis confirmed by histology\u002Fcytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants\n* Disease that is not amenable to curative surgical and\u002For locoregional therapies\n* No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and\u002For unresectable HCC\n* Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days prior to initiation of study treatment\n* Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment\n* Adequate hematologic and end-organ function\n* Life expectancy of at least 12 weeks\n* Female participants of childbearing potential must be willing to avoid pregnancy and egg donation\n* Absolute neutrophil count ≥1.0 x 10\\^9 per liter (\u002FL) (≥1000 per microliter \\[\u002FμL\\]) without granulocyte colony-stimulating factor support\n* Platelet count ≥ 50 × 109\u002FL (50,000\u002FμL) without transfusion\n* Hemoglobin ≥ 80 grams per liter (g\u002FL) (8 grams per deciliter \\[g\u002FdL\\]) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal (ULN)\n* Serum bilirubin ≤ 3 × ULN\n* Creatinine clearance ≥ 50 milliliters per minute (mL\u002Fmin) (calculated using the Cockcroft-gault formula)\n* Serum albumin ≥ 20 g\u002FL (2.0 g\u002FdL) without transfusion in the prior 3 months\n* International normalized ratio (INR) ≤2.3\n\nGeneral Exclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure\n* Treatment with systemic immunostimulatory agents\n* Treatment with systemic immunosuppressive medication\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment\n* Inadequately controlled hypertension\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation\n* Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded\n* Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Prior allogeneic stem cell or solid organ transplantation\n* Actively listed for liver transplantation\n* Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)\n* Untreated or incompletely treated esophageal and\u002For gastric varices with bleeding or that are at high risk for bleeding\n* A prior bleeding event due to esophageal and\u002For gastric varices within 6 months prior to initiation of study treatment\n* Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment\n* Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment\n* History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B\n* Diagnostic paracentesis is allowed. Therapeutic paracentesis: one large volume paracentesis prior to enrollment with diuretic controlled ascites is allowed.\n* Participants with ascites controlled on diuretics are allowed\n* History of spontaneous bacterial peritonitis within last 12 months",[117,118],"ADULT","OLDER_ADULT",[120,129,137,144,151,158,165,172,179,186,193,201,209,217,221,229,237,241,245,253,261,265,273,277,285,292,296,304,312,319,326,334,340,344,351,355,363,371,379,387,394,402,409,417,424,432,436,440,444,451,458,462,466,474,481,489,496,500,508],{"facility":121,"city":122,"state":123,"zip":124,"country":125,"geoPoint":126},"University of Arizona Cancer Center","Tucson","Arizona","85724","United States",{"lat":127,"lon":128},32.22174,-110.92648,{"facility":130,"city":131,"state":132,"zip":133,"country":125,"geoPoint":134},"UC San Diego Moores Cancer Center","La Jolla","California","92093",{"lat":135,"lon":136},32.84727,-117.2742,{"facility":138,"city":139,"state":132,"zip":140,"country":125,"geoPoint":141},"University of Southern California-Keck School of Medicine -1975 Zonal Ave","Los Angeles","90089-5601",{"lat":142,"lon":143},34.05223,-118.24368,{"facility":145,"city":146,"state":132,"zip":147,"country":125,"geoPoint":148},"University of Southern California","Newport Beach","92663",{"lat":149,"lon":150},33.61891,-117.92895,{"facility":152,"city":153,"state":132,"zip":154,"country":125,"geoPoint":155},"University of California Irvine Medical Center","Orange","92868",{"lat":156,"lon":157},33.78779,-117.85311,{"facility":159,"city":160,"state":132,"zip":161,"country":125,"geoPoint":162},"California Liver Research Institute","Pasadena","91105-2561",{"lat":163,"lon":164},34.14778,-118.14452,{"facility":166,"city":167,"state":132,"zip":168,"country":125,"geoPoint":169},"University of California Davis Medical Center","Sacramento","95817",{"lat":170,"lon":171},38.58157,-121.4944,{"facility":173,"city":174,"state":132,"zip":175,"country":125,"geoPoint":176},"Stanford Health Care","Stanford","94305",{"lat":177,"lon":178},37.42411,-122.16608,{"facility":180,"city":181,"state":132,"zip":182,"country":125,"geoPoint":183},"Harbor UCLA Medical Center","Torrance","90502-2006",{"lat":184,"lon":185},33.83585,-118.34063,{"facility":187,"city":188,"state":132,"zip":189,"country":125,"geoPoint":190},"Cedars Sinai Comprehensive Transplant Center","West Hollywood","90048-2422",{"lat":191,"lon":192},34.09001,-118.36174,{"facility":194,"city":195,"state":196,"zip":197,"country":125,"geoPoint":198},"Rocky Mountain Cancer Centers (Williams) - USOR","Denver","Colorado","80218-1237",{"lat":199,"lon":200},39.73915,-104.9847,{"facility":202,"city":203,"state":204,"zip":205,"country":125,"geoPoint":206},"Hartford Healthcare Cancer Institute at Hartford Hospital","Hartford","Connecticut","06106",{"lat":207,"lon":208},41.76371,-72.68509,{"facility":210,"city":211,"state":212,"zip":213,"country":125,"geoPoint":214},"George Washington University- Medical Faculty Associates","Washington D.C.","District of Columbia","20037",{"lat":215,"lon":216},38.89511,-77.03637,{"facility":218,"city":211,"state":212,"zip":219,"country":125,"geoPoint":220},"Washington DC VA Medical Center","20422-0001",{"lat":215,"lon":216},{"facility":222,"city":223,"state":224,"zip":225,"country":125,"geoPoint":226},"Orlando Health Inc.","Orlando","Florida","32806",{"lat":227,"lon":228},28.53834,-81.37924,{"facility":230,"city":231,"state":232,"zip":233,"country":125,"geoPoint":234},"Northwestern University","Chicago","Illinois","60611-2908",{"lat":235,"lon":236},41.85003,-87.65005,{"facility":238,"city":231,"state":232,"zip":239,"country":125,"geoPoint":240},"University of Illinois Health Outpatient Care Center","60612-4795",{"lat":235,"lon":236},{"facility":242,"city":231,"state":232,"zip":243,"country":125,"geoPoint":244},"The Duchossois Center for Advanced Medicine","60637-1426",{"lat":235,"lon":236},{"facility":246,"city":247,"state":248,"zip":249,"country":125,"geoPoint":250},"University of Kentucky - Markey Cancer Center","Lexington","Kentucky","40536-7001",{"lat":251,"lon":252},37.98869,-84.47772,{"facility":254,"city":255,"state":256,"zip":257,"country":125,"geoPoint":258},"LSU Health Baton Rouge","Baton Rouge","Louisiana","70805",{"lat":259,"lon":260},30.44332,-91.18747,{"facility":262,"city":255,"state":256,"zip":263,"country":125,"geoPoint":264},"Our Lady of the Lake Cancer Institute","70808-4300",{"lat":259,"lon":260},{"facility":266,"city":267,"state":268,"zip":269,"country":125,"geoPoint":270},"Tufts Medical Center","Boston","Massachusetts","02111",{"lat":271,"lon":272},42.35843,-71.05977,{"facility":274,"city":267,"state":268,"zip":275,"country":125,"geoPoint":276},"Beth Israel Deaconess Medical Center","02215",{"lat":271,"lon":272},{"facility":278,"city":279,"state":280,"zip":281,"country":125,"geoPoint":282},"Veterans Affairs Ann Arbor Healthcare System","Ann Arbor","Michigan","48105",{"lat":283,"lon":284},42.27756,-83.74088,{"facility":286,"city":287,"state":280,"zip":288,"country":125,"geoPoint":289},"Barbara Ann Karmanos Cancer Institute","Detroit","48201",{"lat":290,"lon":291},42.33143,-83.04575,{"facility":293,"city":287,"state":280,"zip":294,"country":125,"geoPoint":295},"Henry Ford Health System","48202",{"lat":290,"lon":291},{"facility":297,"city":298,"state":299,"zip":300,"country":125,"geoPoint":301},"Saint Luke?s Hospital of Kansas City","Kansas City","Missouri","64111",{"lat":302,"lon":303},39.09973,-94.57857,{"facility":305,"city":306,"state":307,"zip":308,"country":125,"geoPoint":309},"MorristownMedicalCenter","Morristown","New Jersey","07962",{"lat":310,"lon":311},40.79677,-74.48154,{"facility":313,"city":314,"state":307,"zip":315,"country":125,"geoPoint":316},"Rutgers Cancer Institute of New Jersey","New Brunswick","08901",{"lat":317,"lon":318},40.48622,-74.45182,{"facility":320,"city":321,"state":307,"zip":322,"country":125,"geoPoint":323},"Rutgers Cancer Institute of New Jersey at University Hospital","Newark","07103",{"lat":324,"lon":325},40.73566,-74.17237,{"facility":327,"city":328,"state":329,"zip":330,"country":125,"geoPoint":331},"NYU Langone Hospital - Long Island","Mineola","New York","11501-4064",{"lat":332,"lon":333},40.74927,-73.64068,{"facility":335,"city":329,"state":329,"zip":336,"country":125,"geoPoint":337},"NYU Langone Medical Center","10016-9451",{"lat":338,"lon":339},40.71427,-74.00597,{"facility":341,"city":329,"state":329,"zip":342,"country":125,"geoPoint":343},"Icahn School of Medicine at Mount Sinai","10029",{"lat":338,"lon":339},{"facility":345,"city":346,"state":329,"zip":347,"country":125,"geoPoint":348},"Montefiore Medical Center","The Bronx","10467",{"lat":349,"lon":350},40.84985,-73.86641,{"facility":352,"city":346,"state":329,"zip":353,"country":125,"geoPoint":354},"James J Peters Veterans Administration Medical Center - NAVREF","10468-3904",{"lat":349,"lon":350},{"facility":356,"city":357,"state":358,"zip":359,"country":125,"geoPoint":360},"Levine Cancer Institute","Charlotte","North Carolina","28204",{"lat":361,"lon":362},35.22709,-80.84313,{"facility":364,"city":365,"state":366,"zip":367,"country":125,"geoPoint":368},"Dayton VA Medical Center - NAVREF - PPDS","Dayton","Ohio","45428-9000",{"lat":369,"lon":370},39.75895,-84.19161,{"facility":372,"city":373,"state":374,"zip":375,"country":125,"geoPoint":376},"The University of Oklahoma Health Sciences Center","Oklahoma City","Oklahoma","73104-5020",{"lat":377,"lon":378},35.46756,-97.51643,{"facility":380,"city":381,"state":382,"zip":383,"country":125,"geoPoint":384},"Kaiser Permanente Westside Medical Center","Hillsboro","Oregon","97124-5806",{"lat":385,"lon":386},45.52289,-122.98983,{"facility":388,"city":389,"state":382,"zip":390,"country":125,"geoPoint":391},"OHSU Knight Cancer Institute Hematology Oncology","Portland","97239-3011",{"lat":392,"lon":393},45.52345,-122.67621,{"facility":395,"city":396,"state":397,"zip":398,"country":125,"geoPoint":399},"Jefferson Health Honickman Center","Philadelphia","Pennsylvania","19107",{"lat":400,"lon":401},39.95238,-75.16362,{"facility":403,"city":404,"state":397,"zip":405,"country":125,"geoPoint":406},"Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS","Pittsburgh","15240",{"lat":407,"lon":408},40.44062,-79.99589,{"facility":410,"city":411,"state":412,"zip":413,"country":125,"geoPoint":414},"The West Clinic (East Campus)","Germantown","Tennessee","38138-1762",{"lat":415,"lon":416},35.08676,-89.81009,{"facility":418,"city":419,"state":412,"zip":420,"country":125,"geoPoint":421},"Nashville General Hospital at Meharry","Nashville","37208-2918",{"lat":422,"lon":423},36.16589,-86.78444,{"facility":425,"city":426,"state":427,"zip":428,"country":125,"geoPoint":429},"Liver Institute at Methodist Dallas","Dallas","Texas","75203-1260",{"lat":430,"lon":431},32.78306,-96.80667,{"facility":433,"city":426,"state":427,"zip":434,"country":125,"geoPoint":435},"Moody Outpatient Center ? Parkland Health","75235",{"lat":430,"lon":431},{"facility":437,"city":426,"state":427,"zip":438,"country":125,"geoPoint":439},"Texas Oncology (Worth) - USOR","75246-2008",{"lat":430,"lon":431},{"facility":441,"city":426,"state":427,"zip":442,"country":125,"geoPoint":443},"University of Texas Southwestern Medical Center","75390-0001",{"lat":430,"lon":431},{"facility":445,"city":446,"state":427,"zip":447,"country":125,"geoPoint":448},"Texas Oncology - Denison Cancer Center","Denison","75020-0084",{"lat":449,"lon":450},33.75566,-96.53666,{"facility":452,"city":453,"state":427,"zip":454,"country":125,"geoPoint":455},"Kelsey Research Foundation","Houston","77025-1669",{"lat":456,"lon":457},29.76328,-95.36327,{"facility":459,"city":453,"state":427,"zip":460,"country":125,"geoPoint":461},"Michael E Debakey VA Medical Center - NAVREF - PPDS","77030-4211",{"lat":456,"lon":457},{"facility":463,"city":453,"state":427,"zip":464,"country":125,"geoPoint":465},"Houston Methodist Hospital","77030",{"lat":456,"lon":457},{"facility":467,"city":468,"state":469,"zip":470,"country":125,"geoPoint":471},"Intermountain Healthcare","Murray","Utah","84107-5741",{"lat":472,"lon":473},40.66689,-111.88799,{"facility":475,"city":476,"state":469,"zip":477,"country":125,"geoPoint":478},"Intermountain Cancer Center","St. George","84790",{"lat":479,"lon":480},37.10415,-113.58412,{"facility":482,"city":483,"state":484,"zip":485,"country":125,"geoPoint":486},"Inova Schar Cancer Institute","Falls Church","Virginia","22042",{"lat":487,"lon":488},38.88233,-77.17109,{"facility":490,"city":491,"state":484,"zip":492,"country":125,"geoPoint":493},"Bon Secours St. Mary's Hospital","Richmond","23226-1925",{"lat":494,"lon":495},37.55376,-77.46026,{"facility":497,"city":491,"state":484,"zip":498,"country":125,"geoPoint":499},"VCU Medical Center North Hospital","23298-5028",{"lat":494,"lon":495},{"facility":501,"city":502,"state":503,"zip":504,"country":125,"geoPoint":505},"Virginia Mason Medical Center","Seattle","Washington","98101",{"lat":506,"lon":507},47.60621,-122.33207,{"facility":509,"city":510,"zip":511,"country":512,"geoPoint":513},"Pan American Center for Oncology Trials, LLC","Rio Piedras","00935","Puerto Rico",{"lat":514,"lon":515},18.39745,-66.04989,[],[518],{"name":519,"affiliation":520,"role":521},"Clinical Trials","Hoffmann-La Roche","STUDY_DIRECTOR",[],[],{"nct_id":4,"conditions":525,"biomarkers":526},[19],[],{"nct_id":4,"found":15,"summary":70,"prompt_version":70}]